KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
15.61
+0.44 (2.90%)
Jul 16, 2025, 12:43 PM - Market open
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
n/a
Profits / Employee
-$679,422
Market Cap
776.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KALV News
- 20 hours ago - KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 6 days ago - KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - Business Wire
- 7 days ago - KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning - Seeking Alpha
- 9 days ago - US FDA approves KalVista Pharma's swelling disorder drug - Reuters
- 9 days ago - KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 13 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis - Business Wire